Array Biopharma (ARRY) Tops Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $8.25 -3.4%
Revenue Growth %: -11.6%
Financial Fact:
Cost of revenue: 8.85M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: -11.6%
Financial Fact:
Cost of revenue: 8.85M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.21), $0.01 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $6.07 million versus the consensus estimate of $6.35 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
